- Home
- CURI vs ANTX Comparison
CURI vs ANTX Comparison
Compare CURI & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURI | ANTX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.0M | 172.9M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CURI | ANTX |
|---|---|---|
| Price | $2.91 | $4.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $5.83 | $2.00 |
| AVG Volume (30 Days) | ★ 739.8K | 194.6K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 10.36% | N/A |
| EPS Growth | ★ 54.17 | 32.56 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $78,043,000.00 | N/A |
| Revenue This Year | $14.91 | N/A |
| Revenue Next Year | $12.91 | N/A |
| P/E Ratio | $24.25 | ★ N/A |
| Revenue Growth | ★ 9.52 | N/A |
| 52 Week Low | $2.30 | $1.00 |
| 52 Week High | $5.38 | $7.19 |
Technical Indicators
Market Signals| Indicator | CURI | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 39.02 |
| Support Level | $2.81 | $3.91 |
| Resistance Level | $2.97 | $5.15 |
| Average True Range (ATR) | 0.12 | 0.34 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 57.27 | 21.49 |
Price Performance
Historical ComparisonAbout CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.